-
MGI Tech Partners with Oncoclínicas&Co to Advance Precision Medicine in Brazil
•
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina de Precisão of Oncoclínicas&Co, Latin America’s largest cancer treatment group. The collaboration aims to promote precision medicine innovation in Brazil, offering efficient and personalized cancer diagnosis and treatment. Partnership DetailsThe partnership combines OC Medicina de…
-
MGI Tech’s DNBSEQ-E25 Receives NMPA License as World’s First Self-Luminescent Sequencer
•
China-based gene sequencing specialist MGI Tech Co., Ltd has announced that it has received a medical license from the National Medical Products Administration (NMPA) for its DNBSEQ-E25. This achievement marks the DNBSEQ-E25 as the world’s first gene sequencer based on the principle of self-luminescent sequencing biochemistry, setting a new standard…
-
Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data
•
UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca (AZ, NASDAQ: AZN), which involves the transfer of the UK company’s commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer (NSCLC) study. TRACERx Study: A Pioneering Effort in Tumor Evolution ResearchThe…
-
MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil
•
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic partnership with Sabin Group, one of the largest diagnostic laboratories in Brazil. This collaboration aims to enhance the accessibility and quality of genetic sequencing services, thereby improving the healthcare standards for the Brazilian population. Financial…
-
MGI Tech Co., Ltd Partners with Universidad de San Martín de Porre for Genomic Sequencing Advancement
•
China-based gene sequencing specialist MGI Tech Co., Ltd has announced a collaboration with the Universidad de San Martín de Porre in Peru. The partnership aims to strengthen human genetics research by implementing next-generation genomic sequencing (NGS) technologies in the university’s Genetic and Molecular Biology Research Center laboratory. Enhancing Genetic Heritage…
-
MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping
•
China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration with the Human Cell Atlas (HCA) consortium, marking a significant step forward in the human cell mapping initiative. This partnership aims to expand access to MGI’s proprietary products within the HCA network by offering discounted…
-
U.S. House of Representatives to Review the Biosecure Act Amid Legislative Hurdles
•
The U.S. House of Representatives is slated to take up the contentious Biosecure Act the week commencing September 9, as indicated on a website associated with the legislative body. Initially introduced in January, the bill’s trajectory has been marked by delays, raising questions about its potential progression through the House…
-
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
•
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE), has entered into a research collaboration with Quotient Therapeutics, a Cambridge, Massachusetts-based biotech firm. The partnership will focus on analyzing somatic mutations in diseased patient tissue, with a goal of uncovering new therapeutic approaches for…
-
China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment
•
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval from the National Medical Products Administration (NMPA) for its human ApoE gene polymorphism nucleic acid detection kit, utilizing the PCR fluorescent probe method. This kit is classified as a Category III medical device. The detection…
-
Agilent Technologies and Shanghai Majorbio Bio-pharm Ink Deal to Transform Life Science Research in China
•
Agilent Technologies (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, has announced a strategic collaboration with Shanghai Majorbio Bio-pharm Technology Co., Ltd, a prominent biopharmaceutical company in China. This partnership will provide Majorbio with access to Agilent’s cutting-edge sample quality control solutions and its flagship…
-
Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies
•
Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally, has entered into a strategic partnership with US medical technology giant Becton, Dickinson and Co. (BD). The collaboration focuses on the single cell instrument HT Xpress and the establishment of a joint laboratory dedicated to…
-
BGI Genomics and Technopark Biogen Launch Astana Genetic Center to Boost Genetic Testing in Central Asia
•
Astana Genetic Center, a collaboration between China’s leading genomics company BGI Genomics Co., Ltd (SHE: 300676) and Kazakhstan’s Technopark Biogen, has officially commenced operations. The center, located within the Kazakhstan National Biotechnology Center, is well-equipped with state-of-the-art gene sequencing and genetic data analysis machinery, aiming to facilitate early disease diagnosis…
-
MGI Tech Partners with Predica Diagnostics to Advance RNA Sequencing in Cancer Detection
•
MGI Tech Co., Ltd, a leading gene sequencing specialist based in China, has announced a strategic collaboration with Predica Diagnostics, a Netherlands-based company. Under this partnership, MGI will provide support to Predica in the development of targeted RNA sequencing tests utilizing MGI’s next-generation sequencing platforms. While the financial details of…
-
BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province
•
BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced that its subsidiary, Heilongjiang BGI Longjiang Medical Laboratory Co., Ltd, has entered into a three-year cooperation agreement with the Health Commission of Heilongjiang Province. This agreement focuses on providing noninvasive prenatal genetic testing services for…
-
Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China
•
Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership with fellow Chinese firm MGI Tech Co., Ltd. (SHA: 688114). This collaboration will result in the creation of Kindstar’s multi-omics DCS Lab service center, which will be focused on serving the Central China region. Kindstar…
-
Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly acknowledge actively revising its partnerships with China-based Contract Research, Development, and Manufacturing Organizations (CRDMOs) in light of the proposed BioSecure Act in the United States. During a press call with US media accompanying the company’s…
-
US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties
•
Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to influence discourse surrounding China’s biotech sector. This week, Gallagher, along with Republican Raja Krishnamoorthi, sent a letter to US Defense Secretary Lloyd Austin, inquiring about updates on a Pentagon security review of several Chinese biotechnology…
-
China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology
•
The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9 gene editing technology, rejecting an invalidation challenge. The decision was announced by ERS Genomics Ltd, an Ireland-based company founded by Dr. Emmanuelle Charpentier, the Nobel prize-winning co-inventor of the technology, to manage and license access…
-
Bayer and Thermo Fisher Partner to Develop Rapid Companion Diagnostics for Precision Oncology
•
Germany’s Bayer (NYSE: BAYE) has entered into a strategic partnership with U.S. life sciences leader Thermo Fisher Scientific (NYSE: TMO) to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) aimed at enhancing precision cancer therapies. Financial terms of the collaboration remain undisclosed. According to the press release, the diagnostic tests…
-
MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe
•
MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins Genomics Europe Genotyping A/S, headquartered in France. As part of the deal, Eurofins has placed a corporate order for MGI’s DNBSEQ-T20×2 (T20) ultra-high throughput sequencer, which is accompanied by the genomics data center ZTRON Appliance,…
